Private Advisor Group LLC increased its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX – Free Report) by 230.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,017 shares of the company’s stock after purchasing an additional 6,987 shares during the period. Private Advisor Group LLC’s holdings in TransMedics Group were worth $1,509,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. Charles Schwab Investment Management Inc. increased its holdings in TransMedics Group by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 253,517 shares of the company’s stock worth $20,010,000 after purchasing an additional 4,343 shares in the last quarter. Envestnet Portfolio Solutions Inc. raised its position in TransMedics Group by 68.8% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 6,261 shares of the company’s stock valued at $494,000 after buying an additional 2,551 shares during the last quarter. Principal Financial Group Inc. lifted its stake in TransMedics Group by 21.3% in the 4th quarter. Principal Financial Group Inc. now owns 21,929 shares of the company’s stock valued at $1,731,000 after acquiring an additional 3,858 shares in the last quarter. Level Four Advisory Services LLC acquired a new position in TransMedics Group during the 4th quarter worth approximately $471,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of TransMedics Group during the 4th quarter worth approximately $889,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at TransMedics Group
In related news, insider Nicholas Corcoran sold 10,000 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the transaction, the insider now owns 21,105 shares in the company, valued at approximately $3,714,902.10. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $145.17, for a total value of $1,252,091.25. Following the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at $8,948,714.31. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Nicholas Corcoran sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the transaction, the insider now directly owns 21,105 shares in the company, valued at $3,714,902.10. The disclosure for this sale can be found here. In the last 90 days, insiders sold 52,622 shares of company stock worth $8,327,633. 7.00% of the stock is owned by insiders.
Analysts Set New Price Targets
Read Our Latest Stock Analysis on TMDX
TransMedics Group Stock Performance
TMDX opened at $151.42 on Friday. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. TransMedics Group, Inc. has a 12-month low of $36.42 and a 12-month high of $177.37. The business has a 50 day moving average of $154.20 and a 200-day moving average of $126.66. The stock has a market cap of $5.05 billion, a price-to-earnings ratio of -445.35 and a beta of 1.99.
TransMedics Group (NASDAQ:TMDX – Get Free Report) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.14. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The business had revenue of $114.30 million during the quarter, compared to the consensus estimate of $98.84 million. During the same quarter last year, the firm posted ($0.03) EPS. The company’s quarterly revenue was up 117.7% on a year-over-year basis. On average, equities research analysts expect that TransMedics Group, Inc. will post 1.23 earnings per share for the current year.
TransMedics Group Profile
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Further Reading
- Five stocks we like better than TransMedics Group
- How to Most Effectively Use the MarketBeat Earnings Screener
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
- How to Invest in the FAANG Stocks
- Kroger Stock is a Win-Win for Buy-and-Hold Investors
- What are earnings reports?
- MarketBeat Week in Review – 9/9 – 9/13
Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX – Free Report).
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.